Ladenburg Thalmann initiated coverage on Big Cypress Acquisition with a new price target
$BCYP
Finance
Ladenburg Thalmann initiated coverage of Big Cypress Acquisition with a rating of Buy and set a new price target of $16.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/4/2021 | $18.00 | Outperform | Northland Capital Markets |
| 10/1/2021 | $16.50 | Buy | Ladenburg Thalmann |
8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
25-NSE - Big Cypress Acquisition Corp. (0001833214) (Subject)
8-K - Big Cypress Acquisition Corp. (0001833214) (Filer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol "SABS" SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of its business combination with Big Cypress Acquisition Corp. (NASDAQ:BCYP) ("Big Cypress"), a publicly-traded special purpose acquisition company (SPAC) focused on innovative biopharmaceutical
MIAMI, Oct. 21, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ:BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease and immune system disorders, at a Special Meeting of stockholders held on October 20, 2021 (the "Special Meeting"). Approximately 98.3% of t
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m. ET to showcase its versatile DiversitAb™ platform and pipeline of clinical and preclinical programs. The event will feature SAB management and key opinion leaders, including: Arturo Casadevall, MD, PhD – The Alfred and Jill Sommer Professor and Chair, W. Harry Feinstone Department of Molecular Microbiology & Immunology, Bloomberg Distinguished Professor, Johns Hopkins B
Northland Capital Markets initiated coverage of Big Cypress Acquisition with a rating of Outperform and set a new price target of $18.00
Ladenburg Thalmann initiated coverage of Big Cypress Acquisition with a rating of Buy and set a new price target of $16.50
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021. Mr. Beyer will lead all aspects of SAB's financial operations and key supporting functions and will work with the senior management team to drive SAB's growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005435/en/(Photo: Business Wire) "We welcome Russell to the SAB team at an exciting t
SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)
SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)
SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)